Cargando…
AAV Vector-Mediated Antibody Delivery (A-MAD) in the Central Nervous System
In the last four decades, monoclonal antibodies and their derivatives have emerged as a powerful class of therapeutics, largely due to their exquisite targeting specificity. Several clinical areas, most notably oncology and autoimmune disorders, have seen the successful introduction of monoclonal-ba...
Autores principales: | Marino, Marika, Holt, Matthew G. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9039256/ https://www.ncbi.nlm.nih.gov/pubmed/35493843 http://dx.doi.org/10.3389/fneur.2022.870799 |
Ejemplares similares
-
Engineered AAV vectors for improved central nervous system gene delivery
por: A Kotterman, Melissa, et al.
Publicado: (2015) -
Engineered AAVs for efficient noninvasive gene delivery to the central and peripheral nervous systems
por: Chan, Ken Y, et al.
Publicado: (2017) -
Coronaviruses and Central Nervous System Manifestations
por: Khateb, Mohamed, et al.
Publicado: (2020) -
Galectin-3 in Microglia-Mediated Neuroinflammation: Implications for Central Nervous System Diseases
por: Ge, Meng-Meng, et al.
Publicado: (2022) -
AAV9-mediated central nervous system–targeted gene delivery via cisterna magna route in mice
por: Lukashchuk, Vera, et al.
Publicado: (2016)